One of the most common diagnostic tools used to detect problems in the female reproductive system is transvaginal ultrasound. What should you anticipate during this procedure?
{Common Reasons for Pelvic Ultrasound}
Common indications for a pelvic ultrasound include abnormal vaginal bleeding, confirming pregnancy, assessing the cervix, and investigating a family history of ovarian cancer.
We will delve deeper into these conditions shortly.
After the ultrasound procedure, the sonographer will review the images and send a report to your doctor, who will then discuss the results with you.
It is important to follow any instructions given by your healthcare provider following the ultrasound, as additional tests or treatments may be required based on the findings.
Pelvic ultrasounds are commonly used to investigate conditions such as pelvic pain, abnormal bleeding, and infertility issues.
Overall, a pelvic ultrasound is a safe and non-invasive procedure that can provide valuable information about your reproductive health.
{The Sonographer}
The healthcare professional performing the ultrasound, known as a sonographer or technologist, is a skilled expert with advanced qualifications.
{Causes and Management of Pelvic Pain}
If you experience pelvic pain, consult your healthcare provider to identify the root cause, as it can stem from various systems like the reproductive, urinary, or digestive tract.
Possible Causes of Pelvic Pain
Pelvic discomfort can arise from infections, inflammation, bladder disorders, or muscle injuries. A comprehensive evaluation involving medical history and imaging tests like ultrasound can aid in diagnosis.
Diagnostic imaging services are available through the NHS or private clinics offering ultrasound and screening tests.
Treatment Options based on Diagnosis
The course of treatment hinges on the underlying diagnosis. Treatment modalities may range from antibiotic therapy for urinary or vaginal infections to hospital-based pharmacological interventions for conditions like PID.
Menstrual pains can often be alleviated with anti-inflammatory medications like ibuprofen, which block prostaglandin production responsible for uterine contractions. Hormonal therapy, including oral contraceptives, may be utilized for diagnostic purposes.
Surgical interventions may be warranted for specific pelvic pain conditions, each tailored to the diagnosis. Your doctor will discuss treatment options, risks, benefits, and success rates based on your individual case.
In addition to medical treatments, lifestyle changes such as regular exercise, stress management techniques, and dietary modifications may also play a role in managing and improving symptoms associated with pelvic pain.
{Chronic Pelvic Pain Causes and Therapies}
Chronic pelvic pain, whether persistent or cyclical, can stem from various conditions. Diagnosing the specific cause often involves a process of elimination and a range of tests to pinpoint the underlying issue.
For women grappling with chronic pelvic pain, persistence throughout the diagnostic journey is key. Collaborating openly with your healthcare provider offers the best chance of identifying a treatment strategy that suits your needs.
{Identifying Dysfunctional Uterine Bleeding (DUB)}
DUB is the leading cause of abnormal vaginal bleeding in women of reproductive age. The diagnosis of DUB is typically reached after excluding other organic or structural causes of abnormal genital bleeding.
Within a normal menstrual cycle, menstruation typically occurs every 21-35 days, lasting 2-7 days with an average blood loss of 35-150 ml. This translates to 8 or fewer fully soaked pads daily, with usually no more than 2 heavy days.
Pathophysiology of DUB
Throughout a regular menstrual cycle, the menstrual phase starts with menstruation and involves the disintegration and shedding of the functional layer of the endometrium. The proliferative (follicular) phase extends from day 5 to day 14 of the standard cycle and is characterized by endometrial proliferation driven by estrogen stimulation. Estrogen is produced by developing ovarian follicles under the influence of follicle-stimulating hormone (FSH). Endometrial cell proliferation is prominent, with the length and complex structure of spiral arteries increasing. This phase ends when estrogen production peaks, leading to an FSH and luteinizing hormone (LH) surge.
Subsequent follicular rupture during ovulation marks the beginning of the secretory (luteal) phase, characterized by progesterone production and less potent estrogen by the corpus luteum. Proliferation of the functional endometrial layer occurs, and the stroma becomes edematous. Without conception, estrogen and progesterone negatively feedback to the hypothalamus, diminishing FSH and LH production. Spiral arteries contract and experience reduced blood flow. At the cycle’s end, they alternatingly contract and relax, inducing functional layer breakdown and the onset of menstruation.
Approximately 90% of DUB cases result from anovulation, while the remaining 10% align with ovulatory cycles. In an anovulatory cycle, the absence of a corpus luteum formation disrupts typical cyclical progesterone release. This leads to continuous unopposed estradiol production, prompting excessive endometrial growth. Without progesterone, the endometrium proliferates, eventually outstripping its blood supply, culminating in necrosis. The consequence is an excess of uterine bleeding.
In ovulatory DUB, prolonged progesterone secretion triggers irregular endometrial shedding. This is likely linked to a constant low estrogen level, hovering around the bleeding threshold. This engenders endometrial part degeneration and spotting. Progesterone catalyzes the enzymatic conversion of estradiol to the less active estrone. Intriguingly, the endometrial alterations remain sectorial within the glands. Patients exhibiting such symptoms in the reproductive age often have ovulatory cycles or secondary etiologies for hypothalamic dysfunction (e.g., polycystic ovary syndrome).
Uterine bleeding from dysfunctional causes can be characterized as:
* Menorrhagia – Prolonged (>7 days) or excessive (>80 ml per day) uterine bleeding occurring at specific intervals
* Metrorrhagia – Uterine bleeding occurring at irregular and more frequent intervals than usual
* Menometrorrhagia – Prolonged or excessive uterine bleeding occurring at irregular and more frequent intervals than usual
* Intermenstrual bleeding (spotting) – Uterine bleeding of variable volume occurring between regular menstrual periods
* Polymenorrhea – Uterine bleeding occurring at regular intervals less than 21 days
* Oligomenorrhea – Uterine bleeding occurring at intervals from 35 days to 6 months
* Amenorrhea – Absence of uterine bleeding for 6 months or longer
Main categories of DUB include the following:
* Bleeding due to estrogen breakthrough
* Bleeding due to estrogen withdrawal
* Bleeding due to progestin breakthrough
Up to 10% of women with normal ovulatory cycles experience DUB. Women with excess weight often have menstrual cycle instabilities due to non-ovarian endogenous estrogen production, often associated with their fat tissue level. This usually leads to cycles of amenorrhea alternating with metrorrhagia or menometrorrhagia.
There is no cultural predisposition for this condition. However, countries with a large number of female athletes, including the USA, are more likely to encounter this condition. Athletes often experience a loss of LH surge, as well as luteal phase deficiency. This is characterized by a shortened luteal phase due to insufficient production or action of progesterone. This insufficient progesterone stimulus may exist with high, low, strictly 18 months from the onset of menstruation. Menopausal symptoms may first manifest signs of ovarian insufficiency. Patients over 40 years old experience a decrease in ovarian quality. Estrogen hyperplasia causes bleeding in the second phase of the menstrual cycle.
Patients usually complain of amenorrhea, abnormal bleeding. To assess the bleeding condition, ask patients how often they use pads in a regular cycle. Women over 40 may experience hypovolemia, which can lead to hemodynamic instability. Doctors should pay attention to signs of hypovolemia, diabetes, hypertension, hyperthyroidism, liver diseases, medication use, and alternative medicine.
Patients with bleeding may show various pathological manifestations. Primary genital discharges may be associated with increased estrogen production in the body. Many organic pathologies can cause abnormal bleeding in women. Cancer, hemorrhagic disease, endometritis, and polyps can all lead to uncontrolled bleeding. Incomplete bleeding may be indicative of pregnancy. Women taking oral contraceptives should be cautious as this may cause disturbances in the body. Ultrasound has been a huge breakthrough in the diagnosis of pregnant women. It is safe for the fetus and provides accurate results. Ultrasound scanning can be used to determine the gestational age, identify problems during pregnancy such as fetal and organ development pathologies, and much more. Ectopic pregnancy can be dangerous for the mother. An adverse outcome is a common consequence of ectopic pregnancy. It is important to be aware of the first signs, which may include pain, bleeding, and changes in general well-being.
An ectopic pregnancy occurs when a fertilized egg is blocked from reaching the uterus. Causes include infections, inflammation, endometriosis, scar tissue, or birth defects affecting the fallopian tube.
In the emergency department, abdominal pain prompts a urine pregnancy test. A quantitative hCG blood test and ultrasound may follow, detecting low hCG levels or abnormalities that suggest ectopic pregnancy.
Treatment options for ectopic pregnancy depend on medical stability. Methods range from methotrexate injections for early cases to surgical removal, either via major operation or laparoscopy for more advanced pregnancies.
After an ectopic pregnancy, fertility challenges may arise. Risks increase with future pregnancies, especially for women over 35 with prior ectopic pregnancies, PID, fallopian tube surgery, or infertility issues.
To lower the risk of ectopic pregnancy, consider lifestyle changes and consult with a doctor before conception. Early detection is crucial, so seek immediate medical attention if symptoms arise.
Early detection of ovarian cancer significantly improves survival rates. Regular pelvic exams and Pap tests can assist in identifying reproductive system cancers at an early stage.
Ovarian cancers often present no symptoms initially. Seek medical advice if persistent symptoms such as abdominal swelling, pain, or urinary changes occur to rule out ovarian cancer or other conditions.
Screening tests like transvaginal ultrasound and CA-125 blood tests aim to detect ovarian cancer before symptoms appear. While these tests may not always indicate cancer, they can guide further evaluation and treatment decisions.
CA-125 level testing is not considered as effective as ovarian cancer screening method. The main problem with using this test for screening is that besides cancer, other common conditions can also cause elevated CA-125 levels. In women without an ovarian cancer diagnosis, a high CA-125 level is often caused by one of these conditions, not ovarian cancer. Also, not everyone with ovarian cancer has elevated CA-125 levels. If a person who doesn’t have ovarian cancer is found to have abnormally high CA-125 levels, the doctor may repeat the test (to confirm results). The doctor may also recommend having a transvaginal ultrasound.
For women at average risk of ovarian cancer, studies have shown that using transvaginal ultrasound and CA-125 for screening led to additional tests and sometimes more complex surgeries, but did not reduce ovarian cancer mortality. Therefore, no major medical or professional organization recommends routine use of transvaginal ultrasound or blood tests for CA-125 for ovarian cancer screening.
Some organizations argue that these tests can be offered for screening women at high risk of ovarian cancer due to an inherited genetic syndrome. However, even in these women, it is not clear that using these tests for screening reduces the likelihood of dying from ovarian cancer.
Researchers continue to seek more effective screening methods for ovarian cancer. Improvements in screening tests are expected to ultimately lead to a reduction in ovarian cancer mortality.
There are no recommended screening tests for germ cell tumors and stromal tumors. Some germ cell tumors release specific protein markers, such as human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) into the blood. After these tumors have been treated with surgery and chemotherapy, blood tests for these markers can be used to assess treatment effectiveness and identify cancer recurrence.
Researchers continue to search for new tests for early ovarian cancer detection, but as of now, there are no reliable screening tests.
BRCA mutation – a mutation in the BRCA1 and BRCA2 genes, which are tumor suppressor genes. Hundreds of different types of mutations have been identified in these genes, some of which are recognized as harmful, while others are harmless or of unknown impact. Harmful mutations in these genes can cause hereditary breast and ovarian cancer syndrome. Only 5-10% of cases of breast cancer in women are attributed to mutations in BRCA1 and BRCA2, but the impact on women with a mutation in the gene is more significant. Women with harmful mutations in BRCA1 or BRCA2 are at about five times higher risk for breast cancer and about ten to thirty times higher risk for ovarian cancer than usual. The risk of breast and ovarian cancer is higher for women with a high risk of BRCA1 mutation compared to BRCA2 mutation. Having a high-risk mutation does not guarantee that a woman will develop any type of cancer or imply that any cancer that develops was actually caused by the mutation, not another factor.
Genetic counseling is usually recommended for people whose personal or family health history indicates a higher likelihood of mutation. Genetic counselors are health specialists trained to explain genetics to people; some of them are also licensed to register as nurses or social workers. A genetic doctor is a doctor specializing in genetics. The goal of genetic counseling is to inform the individual about the likelihood of a positive result, the risks and benefits of testing, test limitations, practical significance of results, and risk-reduction actions that can be taken in case of a positive result. They are also trained to support individuals during emotional reactions and to be neutral, helping the client make their own decision within the framework of informed consent, without insisting that the client do the same as the consultant. Since knowledge of the mutation can cause significant anxiety, some individuals choose not to undergo testing or postpone it to a later time.
Criteria for mutation testing in BRCA1 or BRCA2 include a family history among 1st, 2nd, or 3rd degree relatives with any of the following:
- Breast cancer diagnosed at age 50 or younger
- Multiple primary breast cancers in one breast or in the opposite breast in one individual
- Both breast and ovarian cancer
- Male breast cancer
- Triple-negative (negative for estrogen receptor, progesterone receptor, and HER2/neu) breast cancer
- Pancreatic cancer with breast or ovarian cancer in the same person or in the same family branch
- Ashkenazi Jewish descent
- Two or more relatives with breast cancer, one of whom is under age 50
- Three or more relatives with breast cancer at any age
- Previously identified BRCA1 or BRCA2 mutation in the family
Testing of young children is considered medically unethical, as the test results will not change the way medical care is provided to the child.
Test procedure
If a client decides to undergo testing, there are two types available. Both are typically done based on blood, although testing can also be done using saliva. The quickest, simplest, and least expensive test utilizes a positive result from a blood relative and checks for only a single known mutation present in the family. If no blood relative has previously reported positive test results, then a full test can be conducted, which examines the entire genome for both BRCA1 and BRCA2. In some cases, due to the founder effect, Jewish ethnicity can be used to narrow testing to quickly check for the three most common mutations found among Ashkenazi Jews.
Testing is usually covered by health insurance and government healthcare programs for individuals at high risk of a mutation, and is not reimbursed for individuals at low risk. The goal of restricting testing for high-risk individuals is to increase the likelihood of getting a meaningful, actionable result from the test, rather than identifying a variant of uncertain significance (VUS). In Canada, individuals confirming their high-risk status through specific criteria are first referred to a specialized hereditary cancer program, and if they choose to undergo testing, the test cost is fully covered. In the USA in 2010, single-site testing had a retail cost of $400 to $500, while full analysis cost around $3000 per gene, with insurance often covering these expenses for recognized high-risk individuals.
The test is ordered by a physician, typically an oncologist, and results are always returned to the physician, not directly to the patient. The speed of result return depends on the test – analysis of a single mutation requires less time in the laboratory – and the available infrastructure. In the USA, test results are usually returned within a week or a few weeks; in Canada, patients typically wait eight to ten months to receive test results.
Test interpretation
A positive test result for a known harmful mutation is evidence of predisposition, although it does not guarantee the development of any type of cancer. A negative test result, if a specific mutation known to be present in the family, shows that the person does not have a BRCA predisposition to cancer, although it does not guarantee that the person will not develop cancer unrelated to the family. A negative test result on its own does not mean that the patient does not have a hereditary predisposition to breast or ovarian cancer. There may be some other genetic predisposition to cancer within the family relating to a different gene.